Discover the full directors' dealings record of Axcelis Technologies INC, a listed equity based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Operating in the Technology sector, Axcelis Technologies INC has published 98 insider filings. Market capitalisation: €2.5bn. The latest transaction was reported on 15 May 2026 — Cession. Among the most active insiders: Lawson Douglas A.. Every trade is accessible without an account.
0 of 0 declarations
Axcelis Technologies Inc. (ticker ACLS) is a U.S.-based semiconductor equipment company listed on the Nasdaq market in the United States. For French-speaking investors, it is best understood as a highly specialized capital equipment supplier focused on a critical, technically demanding step in chip manufacturing rather than as a broad-based semiconductor play. The company’s business dates back to 1978, its current corporate entity was incorporated in Delaware in 1995, and its global headquarters are in Beverly, Massachusetts. Axcelis designs, manufactures, and services ion implantation systems, which are essential tools used in the fabrication of integrated circuits. Its Purion product family is the core of the portfolio and is positioned as one of the company’s key competitive assets. Axcelis’ revenue model combines original equipment sales with a meaningful aftermarket and lifecycle-services stream. Beyond systems, the company provides spare parts, used tools, upgrades, maintenance services, and customer training, helping support customer productivity over the full installed base lifecycle. In its 2024 annual reporting, Axcelis stated that ion implantation accounted for the overwhelming majority of revenue, underscoring the company’s narrow but deep specialization. The firm also highlights a global installed base of more than 3,000 tools and support activity across 10 countries, indicating an international footprint even though the operating center remains firmly U.S.-based. From a competitive standpoint, Axcelis occupies a strong niche in ion implantation and emphasizes leadership in implant-intensive power-device applications. That segment has benefited from secular trends such as electrification, silicon carbide adoption, and next-generation power architectures. The company has positioned its latest products, including the Purion Power Series+ platform and the Purion H6 high-current implanter, around customer needs for higher productivity, precision, purity, reliability, and lower cost of ownership. This gives Axcelis a differentiated profile in a market where process performance and service quality matter as much as pure scale. Recent developments have been important for the investment case. In 2025, Axcelis announced a joint development program with GE Aerospace aimed at high-voltage superjunction power devices, reinforcing its exposure to advanced power semiconductors. In early 2026, it unveiled the Purion H6 for advanced semiconductor manufacturing. The company also disclosed approval of its greenhouse-gas reduction targets by the Science Based Targets initiative in March 2026, reflecting rising ESG discipline. Most notably, Axcelis announced a planned combination with Veeco Instruments late in 2025, a transaction intended to create a larger, more diversified semiconductor equipment company. For investors, the profile is one of focused technology leadership, a valuable installed base, and strategic optionality through sector consolidation.